



UPPSALA  
UNIVERSITET

# Platform for adaptive optimal design of nonlinear mixed effect models

Andrew C. Hooker (1)  
*Associate Professor of Pharmacometrics*

J. G. Coen van Hasselt (2)


*(1) Department of Pharmaceutical Biosciences, Uppsala University,  
Uppsala, Sweden*

*(2) Department of Clinical Pharmacology, Netherlands Cancer Institute,  
Amsterdam, Netherlands*



UPPSALA  
UNIVERSITET

# Model based drug development





UPPSALA  
UNIVERSITET

# Outline

- Robust optimal design
- Adaptive optimal design (AOD)
- Platform for testing and performing AOD trials (DDMORE)
- Exploring AOD
  - Pediatric bridging studies (PK)



# Robust optimal design

- Standard optimal design requires knowledge about the underlying model and parameter values for that model


$$FIM(\text{models}_{fixed}, \text{parameters}_{fixed}, \text{design})$$

- **What if we don't know the model or we don't have a good guess for the parameters of a model?**



## Robust optimal design (2)

- Assume your parameters have distributions
  - (“E-family”, e.g. ElnD)
- Problems if:
  - Distribution does not overlap the true value
  - One region of parameter values “drive” the design





## Robust optimal design (3)

- Incorporate multiple models into your optimization

$$\Psi_{P-D} = \arg \max_{\xi} \left( \sum_i^m \log \left( |FIM(\xi, \Phi^{\{i\}}) |^{\frac{\alpha_i}{p_i}} \right) \right)$$

m=model #,  $\alpha_i$  = weighting and  $p_i$  = # of parameters

- Problems if:
  - “true” model is not one of the candidate models.
  - Parameters are not near the “truth”



UPPSALA  
UNIVERSITET

# Problems with robust design

- If you have too much uncertainty or too many potential models:
  - Rich design covering entire design space is needed
- Are there other ways to deal with uncertainty?



UPPSALA  
UNIVERSITET

# Adaptive Optimal Designs (AOD)


- Another type of robust design
- Adapt and update your understanding of the system (the model) at intermediate steps within a trial, then re-optimize





## Some previous work with AOD

- A recent survey has found that for 10 European pharmaceutical companies the importance of AOD for NLMEM was ranked, on average, 4 on a scale of 5 (Mentre et al. CPT:PSP, 2013).
- Previous work has demonstrated the usefulness of AOD in
  - PET occupancy studies (Zamuner et al. CPT, 2010).
  - bridging studies (Foo and Duffull. Pharm. Res., 2012).
  - population PK in children (Dumont et al. PAGE, 2012).






# AOD the good and the bad


- Good
  - Allows for adjustment of uncertainty in models and parameters
  - Adjustment in misspecification if present
- Bad
  - If you are not wrong from the beginning then adaptations may just introduce error.
  - Adjustments being driven by a small group of patients...may lead to bias.










UPPSALA  
UNIVERSITET

# PLATFORM FOR TESTING AND PERFORMING AOD TRIALS (DDMORE)










**R and P S N**


Stop criterion achieved?

Stop criterion achieved?

Stop criterion achieved?









# Evaluating AODs – Multiple simulations

- Simulate entire process many times (R and PsN)
- Evaluate results in some way (R and PsN)




# For the coming example

- Simulate entire process many times (R and PsN)
- Evaluate results in some way (R and PsN)





UPPSALA  
UNIVERSITET



[poped.sf.net](http://poped.sf.net)

- Optimal experimental design software
- Flexible description of models
- Flexible description of design space
- Flexible design optimization
- Written in Matlab



[psn.sf.net](http://psn.sf.net)

- Perl Speaks NONMEM
- Aids in running nonmem
- Automatic evaluation of complex statistical techniques
- Extraction of important results from NONMEM



UPPSALA  
UNIVERSITET

# AOD prototype

- Modular so that the calls to PopED, PsN and NONMEM can be switched out for other programs.
- General so that “any” model (and adaptation) can be used.
- DDMoRe ([www.ddmore.eu](http://www.ddmore.eu))
  - Platform for AOD
  - Investigate optimal strategies for AOD

Van Hasselt and Hooker, PAGE, 2013

Veronese et al. AODware: a model-based application for optimal and adaptive optimal experimental design exploration, ACOP, 2013



# Exploring AOD – Pediatric PK bridging studies

- Several model types to describe PK changes in children

- Empirical:  $CL_i = CL_{std,i} \cdot \left(\frac{WT_i}{70}\right)^\theta \cdot \dots$

- Holfordian:  $CL_i = CL_{std,i} \cdot \left(\frac{WT_i}{70}\right)^{0.75} \cdot \frac{PMA_i^\gamma}{PMA_i^\gamma + TM_{50}^\gamma} \cdot F_{organ,i} \dots$

- PBPK ...

Anderson and Holford. “Tips and traps analyzing pediatric PK data.” Pediatric Anesthesia, 2011.



# Pediatric PK bridging study

- For this example we chose a somewhat simplistic approach:


$$y_{ij} = \frac{DOSE_i}{V_i} e^{-\left(\frac{CL_i}{V_i}\right) \cdot t_{ij}} \cdot (1 + \varepsilon_{1ij}) + \varepsilon_{2ij}$$

$$CL_i = CL_{BASE,i} + \frac{CL_{MAX} \cdot WT_i^\gamma}{WT 50^\gamma + WT_i^\gamma}$$

$$V_i = V_{STD,i} \cdot (WT_i / 70)$$

$$CL_{BASE,i}, V_{STD,i} \in \text{LogNormal}$$

$$DOSE_i = 1000 \cdot (WT_i / 70)$$








# Pediatric bridging study

- Cohorts optimized on
  - Weights to include in cohort
  - Sampling times.
- Compared the performance of two study design approaches:
  - Fixed optimized design (D-optimal)
  - Adaptive optimized designs (D-optimal).
- For each design approach we evaluated:
  - Different levels of parameter misspecification
- The resulting study designs were evaluated based on:
  - Parameter bias and precision
  - Predicted exposure (AUC).



UPPSALA  
UNIVERSITET

# Fixed D-optimal design with misspecification of WT50




Prior:  $WT50 = 5$

Truth:  $WT50 = 25$



UPPSALA  
UNIVERSITET

# Fixed D-optimal design with misspecification of WT50




Prior: WT50 = 5

Truth: WT50 = 25



UPPSALA  
UNIVERSITET

# Fixed D-optimal design with misspecification of WT50




Prior:  $WT50 = 5$

Truth:  $WT50 = 25$



UPPSALA  
UNIVERSITET


# Fixed D-optimal design with misspecification of WT50





UPPSALA  
UNIVERSITET

# Adaptive D-optimal design with misspecification of WT50




Prior:  $WT50 = 5$

Truth:  $WT50 = 25$



UPPSALA  
UNIVERSITET

# Adaptive D-optimal design with misspecification of WT50




Prior: WT50 = 5

Truth: WT50 = 25



UPPSALA  
UNIVERSITET

# Adaptive D-optimal design with misspecification of WT50








UPPSALA  
UNIVERSITET


# Adaptive D-optimal design with misspecification of WT50





UPPSALA  
UNIVERSITET


# Adaptive D-optimal design with misspecification of WT50





UPPSALA  
UNIVERSITET


# Adaptive D-optimal design with misspecification of WT50






UPPSALA  
UNIVERSITET

# Adaptive D-optimal design with misspecification of WT50






# REE (%) of Parameter estimates






# REE (%) of Parameter estimates





UPPSALA  
UNIVERSITET


# Prediction of AUC for a fixed dose





UPPSALA  
UNIVERSITET

# No Misspecification









UPPSALA  
UNIVERSITET

# No Misspecification





# EMAX misspecification




Prior: EMAX = 0.01

Truth: EMAX = 2



UPPSALA  
UNIVERSITET

# EMAX misspecification




Prior: EMAX = 0.01

Truth: EMAX = 2



UPPSALA  
UNIVERSITET


# Comparing different AOD strategies.





UPPSALA  
UNIVERSITET

# Comparing different AOD strategies (2).





# Conclusions

- We successfully developed an initial implementation of a modular and flexible AOD computational platform, which will be available as freeware when released.
- In many cases AOD can improve parameter precision and accommodate for initial model misspecification compared to standard optimal design techniques.
- If no adaptation is needed or if the adaptation process is not carefully chosen a decrease in parameter precision or even parameter bias can be introduced, demonstrating the need for prior investigation, through simulation, of the AOD process.



UPPSALA  
UNIVERSITET

# Acknowledgements

This work was supported in part by the DDMoRe project ([www.ddmore.eu](http://www.ddmore.eu))

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115156, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. The DDMoRe project is also financially supported by contributions from Academic and SME partners.